[Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis].

Autor:	Li F; Department of Tumor Radiotherapy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China., Xiang J; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.; Department of Respiratory and Critical Medicine, Qijiang District People's Hospital, Chongqing 401420, China., Liu J; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China., Wang X; Department of Respiratory and Critical Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.; Clinical Basis of Respiratory Diseases Key Laboratory of Anhui Province, Bengbu 233004, China., Jiang H; Department of Tumor Radiotherapy, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China.
Jazyk:	čínština
Zdroj:	Nan fang yi ke da xue xue bao = Journal of Southern Medical University [Nan Fang Yi Ke Da Xue Xue Bao] 2024 May 20; Vol. 44 (5), pp. 841-850.
DOI:	10.12122/j.issn.1673-4254.2024.05.05
Abstrakt:	Objective: To explore the molecular mechanism by which FEZF1-AS1 overexpression promotes progression of nonsmall cell lung cancer (NSCLC) via the miR-130a-5p/CCND1 axis. Methods: TCGA database was used to analyze FEZF1-AS1 expression levels in NSCLC. FEZF1-AS1 expression was detected by qRT-PCR in clinical specimens of NSCLC tissues and NSCLC cell lines, and its correlation with clinical features of the patients were analyzed. The binding sites of FEZF1-AS1 with hsa-miR-130a-5p and those of hsa-miR-130a-5p with CCND1 were predicted. CCK8 assay, clone formation assay, scratch assay, and Transwell assay were employed to examine the effects of FEZF1-AS1 knockdown and hsa-miR-130a-5p inhibitor on proliferation, invasion, and migration abilities of lung cancer cell lines. Dual luciferase assay was used to verify the binding of FEZF1-AS1 with hsa-miR-130a-5p and the binding of hsa-miR-130a-5p with CCND1. Western blotting was performed to detect the changes in CCND1 protein expression level in H1299 and H358 cells following FEZF1-AS1 knockdown and treatment with hsa-miR-130a-5p inhibitor. Results: FEZF1-AS1 was highly expressed in NSCLC tissues in close correlation with lymph node metastasis and also in H1299 and H358 cell lines (all P < 0.05). FEZF1-AS1 knockdown obviously reduced proliferation, migration, and invasion abilities of NSCLC cells ( P < 0.05). Dual luciferase assay confirmed the binding of hsa-miR-130a-5p with FEZF1-AS1 and CCND1 ( P < 0.05), and hsa-miR-130a-5p inhibitor significantly inhibited proliferation, migration, and invasion of NSCLC cells ( P < 0.05). FEZF1-AS1 knockdown significantly reduced CCND1 protein expression in NSCLC cells, and this effect was strongly inhibited by treatment with hsa-miR-130a-5p inhibitor ( P < 0.05). Conclusion: FEZF1-AS1 is highly expressed in NSCLC tissue in close correlation with lymph node metastasis to promote cancer progression through the miR-130a-5p/CCND1 axis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu